Decoding age-stratified clinical and molecular heterogeneity in male breast cancer through multiomic profiling. (PubMed, Chin J Cancer Res) - Sep 10, 2026 - "GDSC-guided prioritization with PDO testing nominated sepantronium bromide (YM155) as a candidate vulnerability in YMBC...YMBC patients demonstrated inferior recurrence-free survival, neural signaling enrichment, an immune-cold microenvironment, and enriched NBPF10 mutations. These findings support age as a meaningful stratification variable in MBC risk assessment and treatment planning, and highlight the need for caution when considering treatment de-escalation in younger patients, while nominating YM155 as a candidate agent for prospective evaluation."
Heterogeneity • Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Male Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • HER-2 • NBPF10
|
|
Bingqiu Xiu; Jing Liu; Jingyan Xue; Jiong Wu; Rui Xu; Xiaoting Chen; Yangsiyuan Zhao; Yanhui Wang; Yue Zhou; Zehao Wang; Zhiming Shao; Zhishuang Gao
|